Nonsteroidal antiinflammatory agents - Part 1: Antiinflammatory, analgesic and antipyretic activity of some new 1-(pyrimidin-2-yl)-3- pyrazolin-5-ones and 2-(pyrimidin-2-yl)-1,2,4,5,6,7-hexahydro-3H-indazol-3- ones

European Journal of Medicinal Chemistry

Volumn 33, Issue 5, 1998, Pages 349-361

  Badawey, El Sayed A M ^a   El Ashmawey, Ibrahim M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

2 (pyrimidin 2 yl) 1,2,4,5,6,7 hexahydro 3H indazol 3 one synthesis; 2 acetylbutyrolactone; Analgesic activity; Antiinflammatory activity; Antipyretic activity; L (pyrimidin 2 yl) 3 pyrazolin 5 one synthesis; keto ester

Indexed keywords

1 (PYRIMIDIN 2 YL) 3 PYRAZOLIN 5 DERIVATIVE; 2 (PYRIMIDIN 2 YL) 1,2,4,5,6,7 HEXAHYDRO 3H INDAZOL 3 DERIVATIVE; 2 ACETYLBUTYROLACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION; ULCEROGENESIS;

EID: 0032102385     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(98)80002-0     Document Type: Article

References (25)

1. [1] Rang H.P., Dale M.M., Ritter J.M., Pharmacology, 3rd ed., Churchill Livingstone, 1995, pp. 246-255.
2. [2] Khannaa I.S., Weier R.M., Collins P.W. et al., J. Med. Chem 40 (1997) 1619-1633.
3. [3] Boehm J.C., Smietana J.M., Sorenson M.E. et al., J. Med. Chem. 39 (1996) 3929-3937.
4. [4] Li J.J., Andersen G.D., Reitz D.B. et al., J. Med. Chem. 38 (1995) 4570-4578.
5. [5] Cullen E., J. Pharm. Sci. 73 (1984) 579-589.
6. [6] Reynold J.E.F., Martindale, The Extra Pharmacopeia, 30th ed., Pharmaceutical Press, London, 1993. pp. 1-46.
7. [7] Naito T., Yoshikawa T., Kitahara S.I., Aoki N.E., Chem. Pharm. Bull. 17 (1969) 1467-1478.
8. [8] Oshima Y., Akimoto T., Tsukada W., Yamasaki T., Yamaguchi K., Kojima H., Chem Pharm. Bull. 17 (1969) 1492-1497.
9. [9] Bruneau P, Delvare C., Edwards M.P., McMillan R.M., J. Med. Chem. 34 (1991) 1028-1036.
10. [10] Tse E., Butner L., Huang Y., Hall I.H., Arch. Pharm. Pharm. Med. Chem. 329 (1996) 35-40.
11. [11] Asahi Chemical Industry Co.. Jpn. Kokai Tokkyo J.P. 58,159,471 [83,159,471] (C1 C07D231/56); Chem. Abstr. 101 (1984) 55095u.
12. [12] Asahi Chemical Industry Co., Jpn. Kokai Tokkyo J.P. 58,159,473 [83,159,473] (C1 C07D231/56); Chem. Abstr. 100 (1984) 85688m.
13. [13] Shestakov P., Kazakov N., J. Russ. Phys. Chem. 44 (1913) 12-20; Chem. Abstr. 7 (1913) 984.
14. [13] Shestakov P., Kazakov N., J. Russ. Phys. Chem. 44 (1913) 12-20; Chem. Abstr. 7 (1913) 984.
15. [14] De S.C., Rakshit P.C., J. Indian Chem. Soc. 13 (1936) 509-518.
16. [15] Tsuji T., Ueda T., Chem. Pharm. Bull. 19 (1971) 2530-2533.
17. [16] Hlavka J.J., Bitha P., Lin Y., Strohmeyer T., J. Heterocyclic Chem. 21 (1984) 1537-1541.
18. [17] Badawey E.-S.A.M., Kappe T., Arch. Pharm. Pharm. Med. Chem. 330 (1997) 59-62.
19. [18] Badawey E.-S.A.M., Kappe T., Eur. J. Med. Chem. 30 (1995) 327-332.
20. [19] Badawey E.-S.A.M., Kappe T., J. Heterocyclic Chem. 32 (1995) 1003-1006.
21. [20] Badawey E.-S.A.M., J. Heterocyclic Chem. 33 (1996) 229-233.
22. [21] Singh G.B., Singh S., Bani S., Gupta B.D., Banerjee S.K., J. Pharm. Pharmacol. 44 (1992) 456-458.
23. [22] Reitman S., Frankel S., Am. J. Clin. Path. 26 (1957) 56-60.
24. [23] Daidone G., Maggio B., Raffa D. et al., Eur. J. Med. Chem. 29 (1994) 707-711.
25. [24] Manna F. Chimenti F., Bolasco A. et al., Eur. J. Med. Chem. 27 (1992) 633-639.